GSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024. In the quarter to June 2026, revenue grew 5.81%, EPS fell 69.5%, free cash flow grew 54.8% and total debt rose 5.61%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow GSK
GSK PLC Sponsored ADR (GSK) P/E ratio
As of 16 October 2026, GSK PLC Sponsored ADR (GSK) trades at a P/E ratio of 15.4×. Over the past ten years it has ranged from 3.6× (September 2022) to 1,213× (August 2016); the current reading is higher than 56% of that period. That is below the Drug Manufacturers General industry median of 24.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 13.2× | (37.47%) |
| FY2024 | 21.1× | 70.18% |
| FY2023 | 12.4× | 205.14% |
| FY2022 | 4.1× | (72.19%) |
| FY2021 | 14.6× | 46.69% |
| FY2020 | 10.0× | (36.82%) |
| FY2019 | 15.8× | 0.76% |
| FY2018 | 15.7× | (58.08%) |
| FY2017 | 37.4× | (42.23%) |
| FY2016 | 64.7× | 960.84% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 16.3× | 14.51% |
| Mar 2026 | 14.3× | 7.89% |
| Dec 2025 | 13.2× | 8.72% |
| Sep 2025 | 12.2× | (31.30%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| NVO Novo Nordisk A/S compare | 9.5× |
| BMY Bristol Myers Squibb Company compare | 13.2× |
| GSK GSK PLC Sponsored ADR | 15.4× |
| SNY Sanofi compare | 21.3× |
| NVS Novartis AG compare | 22.6× |
| AZN AstraZeneca PLC compare | 24.5× |
| AMGN Amgen Inc. compare | 26.7× |
| PFE Pfizer Inc. compare | 38.9× |
| Drug Manufacturers General industry median | 24.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)